A nonprofit group called the Medicines Patent Pool has had licensing rights to the drug for the last five years. The deal was criticized for being too restrictive, as high-income countries were denied access to the drug, according to STAT.
Since Kaltera has shown to be somewhat effective in treating COVID-19, AbbVie said it would dedicate the intellectual property rights for the drug to the public.
“The big win here may be for people for HIV. Access to [Kaltera] has been a battle for years,” Ellen ‘t Hoen, a senior researcher in the global health unit at the University of Groningen in the Netherlands, told STAT.
Read the full article here.
More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
